Vascular endothelial growth factor (VEGF) is a potent angiogenic factor, and its signaling can be inhibited by agents such as bevacizumab (a monoclonal antibody against VEGF), and tyrosine kinase inhibitors like sunitinib and sorafenib that target VEGF receptors.292 These agents have shown benefits in various cancers, including colorectal, lung, and renal cell carcinomas, and have become a cornerstone of anti-angiogenic therapy.293. Here, VEGFA is linked to hereditary clear cell renal cell carcinoma.